Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: A Children's Oncology Group Study (CCG-1941)

Pediatric Blood and Cancer

Volumn 47, Issue 2, 2006, Pages 141-146

  Jarrar, Mohammad ^a   Gaynon, Paul S ^a   Periclou, Antonia P ^a   Fu, Cecilia ^a   Harris, Richard E ^a   Stram, Daniel ^a   Altman, Arnold ^a   Bostrom, Bruce ^a   Breneman, John ^a   Steele, David ^a   Trigg, Michael ^a   Zipf, Theodore ^a   Avramis, Vassilios I ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b CHLA   (United States)

Author keywords

Acute lymphoblastic leukemia; Anti asparaginase antibody; Asparaginase; Asparagine; Glutamine; Induction

Indexed keywords

ANTIBODY; ASPARAGINASE; ASPARAGINE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GLUTAMINE; HYDROCORTISONE; IFOSFAMIDE; METHOTREXATE; PEGYLATED ASPARAGINASE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID BLOOD LEVEL; AMINO ACID DEFICIENCY; ANTIBODY TITER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INDUCTION THERAPY; CHILD; CLINICAL PROTOCOL; ENZYME ACTIVITY; ESCHERICHIA COLI; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION;

ANTIBODY FORMATION; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; ASPARAGINE; CHILD; FEMALE; GLUTAMIC ACID; HUMANS; INJECTIONS, INTRAMUSCULAR; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; POLYETHYLENE GLYCOLS; RECURRENCE; REMISSION INDUCTION; STATISTICS, NONPARAMETRIC;

EID: 33745765204     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20713     Document Type: Article

References (42)

1. Kidd JG. Asparaginase and cancer-yesterday and today. Recent Results Cancer Res 1970;33:3-14.
2. Goody HE, Ellem KA. Nutritional effects on precursor uptake and compartmentalization of intracellular pools in relation to RNA synthesis. Biochem Biophys Acta 1975;383:30-39.
3. Story MD, Voehringer DW, Stephens LC, et al. L-asparaginase kills lymphoma cells by apoptosis. Cancer Chemother Pharmacol 1993;32:129-133.
4. Bussolati O, Belletti S, Uggeri J, et al. Characterization of apoptotic phenomena induced by treatment with L-asparaginase in NIH3T3 cells. Exp Cell Res 1995;220:283-291.
5. Ueno T, Ohtawa K, Mitsui K, et al. Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase. Leukemia 1997;11: 1858-1861.
6. Veerman AJ, Kaspers GJ, Pieters R. Cellular drug resistance in childhood leukemia. Ann Hematol 1994;69:S31-S34.
7. Kaspers GJ, Veerman AJ, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997;90:2723-2729.
8. Hutson RG, Kitoh T, Moraga Amador DA, et al. Amino acid control of asparagine synthetase: Relation to asparaginase resistance in human leukemia cells. Am J Physiol 1997;272:C1691-C1699.
9. Aslanian AM, Fletcher BS, Kilberg MS. Asparagine synthetase expression alone is sufficient to induce L-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem J 2001;357:321-328.
10. Aslanian AM, Kilberg MS. Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells. Biochem J 2001;358: 59-67.
11. Andrulis IL, Argonza R, Cairney AE. Molecular and genetic characterization of human cell lines resistant to L-asparaginase and albizziin. Somat Cell Mol Genet 1990;16:59-65.
12. Majlessipour F, Kwock R, Martin-Aragon S, et al. Development of a double-drug-resistant human leukemia model to cytotosine arabinoside and L-asparaginase: Evaluation of cross-resistance to other treatment modalities. Anticancer Res 2001;21:11-22.
13. Kiriyama Y, Kubota M, Takimoto T, et al. Biochemical characterization of U937 cells resistant to L-asparaginase: The role of asparagine synthetase. Leukemia 1989;3:294-297.
14. Stams WAG, den Boer ML, Appel IM, et al. Asparagine synthetase is Inked with L-asparaginase reistance in TEL AML1-negative but not TEL AML1-positive pediatric acute lymphoblastic leukemia. Blood 2005;105:4223-4225.
15. Fine BM, Kaspers GJL, Ho M, et al. A genome-wide review of the in vitro response to L-asparaginase in acute lymphoblastic leukemia. Cancer Res 2005;65:291-299.
16. Sallan SE, Hitchcock-Bryan S, Gelber R, et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983;43:5601-5607.
17. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose as paraginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study. Leukemia 1999;13:335-342.
18. Abshire TC, Pollock BH, Billett AL, et al. Weekly polyethylene glycol conjugated L-asparaginase compared with bi-weekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: A Pediatric Oncology Group Study. Blood 2000;96:1709-1715.
19. Avramis VI, Sencer S, Periclou A, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 2002;99:1986-1994.
20. Dohlwitz A, Franzen S, Holmgren A, et al. Studies on antibody formation in patients treated with L-asparaginase. Recent Results Cancer Res 1970;33:198-203.
21. Fabry U, Korholz D, Jurgens H, et al. Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children-evidence of a complement-mediated mechanism. Pediatr Res 1985;19:400-408.
22. Nesbit M, Chard R, Evans A, et al. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol 1979;1:9-13.
23. Cheung NK, Chau IY, Coccia PF. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol 1986;8:99-104.
24. Woo MH, Hak LJ, Storm MC, et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998;12:1527-1533.
25. Zajaczkowski J, Pituch A, Legutko L, et al. Immunological aspects of L-asparaginase treatment in children with lymphoproliferative disease. Helv Paediatr Acta 1976;30:441-446.
26. Khan A, Hill JM. Neutralizing precipitin in the serum of a patient treated with L-asparaginase. J Lab Clin Med 1969;73:846-852.
27. Kurtzberg J, Asselin B, Pollack B, et al. PEG L-asparaginase (PEGasp) vs. native E coli asparaginase (asp) for reinduction of relapsed acute lymphoblastic leukemia (ALL): Pediatric Oncology Group (POG) 8866 Phase II trial. Proc Annu Meet Am Soc Clin Oncol 1993;12:A1079.
28. Maksimov VI, Molodova GA, Uvarkina TP, et al. Characteristics of asparaginase from Escherichia coli at different stages of purification. Prikl Biokhim Mikrobiol 1976;12:552-556.
29. Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004;26:217-226.
30. Avramis V, Periclou P, Majlessipour F, et al: Population pharmacokinetics (ppk) and pharmacodynamics (ppd) of PEG asparaginase (PEG-ASNase) in pediatric patients with acute lymphoblastic leukemia (ALL): CCG study 1962. Blood 1999;94:295a.
31. Lavi LE, Holcenberg JS, Cole DE, et al. Sensitive analysis for asparagine and glutamine in physiological fluids and cells by precolumn derivitization with phenylisocyanate and reversed-phase high-performance liquid chromatography. J Chromatogr 1986;377:155-163.
32. Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993;11:1780-1786.
33. Kurtzberg J, Asselin BL, Poplack D, et al. Peg L-asparaginase (PEG-ASP) pharmacology in pediatric patients with acute lymphoblastic leukemia (ALL). Proc Am Soc Clin Oncol 1994;13:144.
34. Asselin BL, Lorenson MY, Whitin JC, et al. Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor. Cancer Res 1991;51: 6568-6573.
35. Riccardi R, Holcenberg IS, Glaubiger DL, et al. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981;41:4554-4558.
36. Gentili D, Zucchetti M, Conter V, et al. Determination of L-asparagine in biological samples in the presence of L-asparaginase. J Chromatogr B Biomed Appl 1994;657:47-5237.
37. Woo MH, Hak LJ, Storm MC, et al. Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. J Clin Oncol 1999;17:1568-1573.
38. Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996;32A:1544-1550.
39. Ahlke E, Nowak-Gottl U, Schulze-Westhoff P, et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol 1997;96:675-681.
40. Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol 1999;457:621-629.
41. Gentili D, Conter V, Rizzari C, et al. L-Asparagine depletion in plasma and cerebrospinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase [see comments]. Ann Oncol 1996:7:725-730.
42. Appel IM, Pinheiro JP, den Boar ML, et al. Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG asparaginase: A window study at initial diagnosis of childhood ALL. Leukemia 2003;17:2254-2256.